Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3Dprinted at a scale and resolution that was previously unattainable.
Our innovation 3DPDMS creates microfluidicsin the industry-standard material at a speed andresolution to create true biological models thatpropel bioinnovation across the biotech industry.
Backed by two NIH grants, Phase, Inc. is currently working with HarvardMedical School, Georgia Tech, and Virginia Tech to develop a microfluidicdevice that will allow researchers to develop new brain cancer treatments.
With a team of seasoned leaders in both 3D printingand biomedical engineering with advanced degrees fromMIT and UC Berkeley, Phase is poised to lead the microfluidicsindustry in unlocking the next wave of medical breakthroughs.
11148 Treynorth Drive, Suite A
Cornelius, North Carolina 28031
